Aug 27 (Reuters) - AstraZeneca said on Thursday its asthma drug Tezspire met the main goals of a late-stage trial in patients ...

In its release on the CARDIO-TTRansform data, the ESC echoed AZ and Ionis’ point that Wainua suppressed circulating serum TTR ...

Aug 27 (Reuters) - AstraZeneca said on Thursday its asthma drug, Tezspire, developed with Amgen, met its main and secondary ...

AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning ...

Reports of preliminary talks between AstraZeneca and Bristol Myers Squibb moved shares and reignited debate over Big Pharma consolidation.

AstraZeneca detailed the surprise failure of a closely watched heart disease trial, a study with ripple effects for a ...

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) said its drug Tezspire worked in a late-stage trial of patients with eosinophilic ...

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for ...

AstraZeneca PLC (NYSE:AZN) investors received a reassuring earnings report at a sensitive point in the company’s growth story ...

Even without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen’s Tezspire as a potential threat for ...

Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to meet its target, with analysts saying the bigger issue may be investo ...

Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock ...